Clinical Trial Results:
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects with Moderately to Severely Active Crohn’s Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy
Summary
|
|
EudraCT number |
2010-022758-18 |
Trial protocol |
DE AT GB BE CZ IS IE ES DK HU IT |
Global completion date |
03 Jul 2013
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
04 Jun 2016
|
First version publication date |
04 Jun 2016
|
Other versions |
|
Summary report(s) |
CNTO1275CRD3001 (2010-022758-18)_CSR Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.